Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Targeted Drugs With Companion Dx May Draw Medicare NCD Interest – Phurrough

Executive Summary

Targeted drugs indicated for use with companion diagnostics raise the kind of reimbursement concerns that may make them eligible topics for a Medicare national coverage determination, Steve Phurrough, former director of the Centers for Medicare and Medicaid Services coverage and analysis group, suggests.
Advertisement

Related Content

Zelboraf Approval Hastened By FDA Officials Impressed With Early Efficacy
Zelboraf Approval Hastened By FDA Officials Impressed With Early Efficacy
MEDCAC Review Of Anti-VEGF Drugs Rescheduled To March 21, 2012
CMS Maintaining The Status Quo For ESAs In Chronic Renal Disease

Topics

Advertisement
UsernamePublicRestriction

Register

PS053860

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel